In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: Clinical and economic outcomes from the nationwide inpatient sample

Cancer

Volumn 112, Issue 5, 2008, Pages 1096-1105

  Jones, Jeffrey A ^a,b   Qazilbash, Muzaffar H ^a   Shih, Ya Chen T ^a   Cantor, Scott B ^a   Cooksley, Catherine D ^a   Elting, Linda S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Autologous hematopoietic stem cell transplantation; Complications; Cost; Hodgkin disease; Length of stay; Mortality; Multiple myeloma; Non Hodgkin lymphoma

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER MORTALITY; CANCER PATIENT; COHORT ANALYSIS; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INFECTION; LENGTH OF STAY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT OUTCOME; UNITED STATES; VITAL STATISTICS; WHOLE BODY RADIATION;

COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 39749173771     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23281     Document Type: Article

References (33)

1. Harrouseau JL, Greil R, Kloke O; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16(suppl 1):i45-i47.
2. Imrie K, Esmail R, Meyer RM; Members of the Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med. 2002;136:619-629.
3. Shimizu K; Japan Myeloma Study Group. Guidelines for the diagnosis and management of multiple myeloma by the Japan Myeloma Study Group [in Japanese]. Rinsho Ketsueki. 2005;46:424-432.
4. Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410-451.
5. Zelenetz AD, Advani RH, Buadi F, et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:258-310.
6. Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, et al. Hodgkin's disease/lymphoma: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4:210-230.
7. Jost LM, Stahel RA; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol. 2005;16(suppl 1):i54-i55.
8. Center for International Blood and Marrow Transplantation Research (CIBMTR). Current Use and Outcome of Hematopoietic Stem Cell Transplantation 2005. Available at: http://campus.mcw.edu/AngelUploads/Content/CS_IBMTR2/_assoc/ ECCBED0AF0A4492BB667FB6227DC7C06/summaryslides2005_Pt1_files/frame.htm [Accessed October 16, 2006].
9. Bennett CL, Armitage JL, Armitage GO, et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol. 1995;13:969-973.
10. Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004;22:207-224.
11. Sweetenham JW. Economics of stem cell transplantation for lymphoma: counting the cost of living. Br J Cancer. 2000;82:4-6.
12. Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska medical center 1989 to 1995. Bone Marrow Transplant. 1999;24:679-684.
13. Waters TM, Bennett CL, Pajeau TS, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998;21:641-650.
14. Mishra V, Andresen S, Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant. 2005;35:1149-1153.
15. Kouroukis CT, O' Brien BJ, Benger A, et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma. 2003;44:29-37.
16. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol. 2003;25:179-184.
17. Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol. 2001;113:1015-1019.
18. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64-71.
19. Esperou H, Brunot A, Roudot-Thoraval F, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: Results from a prospective, multicenter, French study. Transplantation. 2004;77:1854-1858.
20. Healthcare Cost and Utilization Project (HCUP). HCUP Nationwide Inpatient Sample (NIS). Available at: www.hcup-us.ahrq.gov/nisoverview.jsp
21. United States. Health Care Financing Administration. ICD-9-CM: International Classification of Diseases, Clinical Modification. Vol 91-1260. 4th, 9th revised ed. Washington, DC: US Department of Health and Human Services, Public Health Service, Health Care Financing Administration; US Government Printing Office; 1991.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373-383.
23. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090.
24. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; changes to the hospital inpatient prospective payment systems and rates and costs of graduate medical education: Fiscal year 2002 rates; provisions of the balanced budget refinement act of 1999; and provisions of the Medicare, Medicaid, and SCHIP benefits improvement and protection act of 2000. Final rules. Fed Regist. 2001;66:39827-40102.
25. US Department of Labor Bureau of Labor Statistics. July 2003 Medicare cost-to-charge reimbursement. Washington, DC: US Department of Labor; 2004.
26. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197-1200.
27. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
28. Buchali A, Feyer P, Groll J, Massenkeil G, Arnold R, Budach V. Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. Radiother Oncol. 2000;54:157-162.
29. Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant. 2003;32:279-285.
30. Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001;28:455-461.
31. Stiff PJ, Unger JM, Forman SJ, et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003;9:529-539.
32. Newhouse J. Medical care costs: how much welfare loss? J Econ Perspectives. 1992;6:3-21.
33. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. 3rd ed. Chicago. Health Administration Press; 2003.